WATCHMAN FLX Left Atrial Appendage Closure Device

Built on the most studied and implanted LAAC device in the world, WATCHMAN FLX is designed to advance procedural performance and safety while expanding the treatable patient population

PINNACLE FLX Pivotal Trial Results

The PINNACLE FLX US IDE Clinical Study was designed to establish the procedural safety and closure efficacy of next generation LAAC device, WATCHMAN FLX

ADVANCE SAFETY

Proven Safety Outcomes

The low 0.5% event rate demonstrates the enhanced safety profile of the WATCHMAN FLX device, showing a statistically significant difference to the performance goal set for similar safety endpoints in the PREVAIL Trial and CAP2 Registry.1 

Occurrence of one of the following events between the time of implant and within 7 days following the procedure or by hospital discharge, whichever is later: all-cause death, ischemic stroke, systemic embolism, or device or procedure related events requiring open cardiac surgery or major endovascular intervention
Based on the combined rate observed in PREVAIL(2) and CAP2(3), plus a clinically acceptable delta
PREVAIL(2) & CAP2(3) studied the WATCHMAN LAAC Device

ADVANCE PROCEDURAL PERFORMANCE

Proven Efficacy Outcomes

The WATCHMAN FLX device is designed for enhanced LAA closure which was demonstrated with 100% rate of effective LAA closure at 12 months.1

* LAA closure at 12 months is defined as any peri-device flow with jet size ≤5mm per core laboratory-assessed TEE
Performance goal based on the rates observed in PREVAIL(2) and CAP2(3), minus a clinically relevant delta

EXPAND THE TREATABLE PATIENT POPULATION

Designed to Treat the Widest Range of Patient Anatomies

Procedure Performance

Broad Range of Anatomies

NOAC Discontinuation

* Procedure success defined as successful delivery and release of a WATCHMAN FLX device into the LAA
Measured maximum LAA ostium width and/or deployed closure device diameter must be ≥ 14.0 mm and ≤ 31.5 mm to accommodate available Closure Device sizes. LAA depth should be approximately half the labeled implant diameter or longer
This figure includes both the main cohort, and roll-in patients (totaling 452 implants)

Be sure to talk with your WATCHMAN Representative for more details on availability in your area.

Don’t have a WATCHMAN representative in your area? Click here to locate a WATCHMAN Implanting Center near you. 

WATCHMAN FLX device

1. PINNACLE FLX. Doshi, SK. Results Presented at HRS 2020.
2. Holmes, DR., et al, (2014). J AM Coll Cardiol 64(1): 1-12.
3. Holmes, DR., et al, JACC 2019.4. Ellis et al. Presented at AF Symposium 2020.
4. Ellis et al. Presented at AF Symposium 2020.

 

CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician. Rx only. Prior to use, please see the complete “Instructions for Use” for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events, and Operator’s Instructions.

INTENDED USE/INDICATIONS FOR USE

The WATCHMAN FLX Device is indicated to reduce the risk of thromboembolism from the left atrial appendage in patients with non-valvular atrial fibrillation who:

  • Are at increased risk for stroke and systemic embolism based on CHADS2 or CHA2DS2-VASc scores and are recommended for anticoagulation therapy;
  • Are deemed by their physicians to be suitable for anticoagulation therapy; and
  • Have an appropriate rationale to seek a non-pharmacologic alternative to anticoagulation therapy, taking into account the safety and effectiveness of the device compared to anticoagulation therapy.

CONTRAINDICATIONS

Do not use the WATCHMAN FLX Device if:

  • Intracardiac thrombus is present.
  • An atrial septal defect repair or closure device or a patent foramen ovale repair or closure device is present.
  • The LAA anatomy will not accommodate a Closure Device (see Table 45 of the eIFU).
  • The patient has a known hypersensitivity to any portion of the device material or the individual components (see Device Description section of the eIFU) such that the use of the WATCHMAN FLX Device is contraindicated.
  • Any of the customary contraindications for other percutaneous catheterization procedure (e.g., patient size too small to accommodate TEE probe or required catheters) or conditions (e.g., active infection, bleeding disorder) are present.
  • There are contraindications to the use of anticoagulation therapy, aspirin, or P2Y12 inhibitor.

WARNINGS

Implantation of the WATCHMAN FLX Device should only be performed by interventional cardiologists and/ or electrophysiologists who are trained in percutaneous and transseptal procedures and who have completed the WATCHMAN FLX Physician Training program.

  • This device has not been studied in pregnant or breastfeeding women. Careful consideration should be given to use of the Closure Device in pregnant and/ or breastfeeding women due to the risk of significant exposure to x-rays and the use of anticoagulation medication.
  • Device selection should be based on accurate LAA measurements obtained using echocardiographic imaging guidance in multiple views (TEE recommended in multiple angles [e.g., 0°, 45°, 90°, 135°]) to avoid improper Closure Device sizing.
  • Do not release (i.e., unscrew) the WATCHMAN FLX Device from the core wire unless all release criteria are satisfied to avoid suboptimal results.
  • Potential for Closure Device embolization exists with cardioversion < 30 days following Closure Device implantation; verify Closure Device position after cardioversion during this period.
  • Appropriate post-procedure drug therapy should be followed. See Post-Procedure Information section (of the eIFU) for further detail.

PRECAUTIONS

  • The safety and effectiveness (and benefit-risk profile) of the WATCHMAN FLX Device has not been established in patients for whom long-term anticoagulation is determined to be contraindicated.
  • The LAA is a thin-walled structure. Use caution when accessing the LAA, and deploying, recapturing, and repositioning the Closure Device.
  • Use caution when introducing a WATCHMAN Access System to prevent damage to cardiac structures.
  • Use caution when introducing the Delivery System to prevent damage to cardiac structures.
  • To prevent damage to the Delivery Catheter or Closure Device, do not allow the WATCHMAN FLX Device to protrude beyond the distal tip of the Delivery Catheter when inserting the Delivery System into the Access Sheath.
  • If using a power injector, the maximum pressure should not exceed 100 psi.

PATIENT SELECTION FOR TREATMENT

In considering the use of the WATCHMAN FLX Device, the rationale for seeking an alternative to long-term anticoagulation therapy and the safety and effectiveness of the device compared to anticoagulation should be taken into account.

  • The presence of indication(s) for long-term anticoagulation therapy, other than non-valvular atrial fibrillation (e.g. mechanical heart valve, hypercoagulable states, recurrent deep venous thrombosis).

Details regarding the indications, contraindications, warnings, and precautions for oral anticoagulants approved for patients with non-valvular atrial fibrillation are provided in their respective Instructions for Use. Of note:

  • The safety and effectiveness (and benefit-risk profile) of the WATCHMAN FLX Device has not been established in patients for whom long-term anticoagulation is determined to be contraindicated.
  • Factors that need to be considered for the WATCHMAN FLX Device and implantation procedure include the following:

  • Overall medical status, including conditions which might preclude the safety of a percutaneous, transcatheter procedure.
  • Suitability for percutaneous, transseptal procedures, including considerations of:
    • Cardiac anatomy relating to the LAA size and shape.
    • Vascular access anatomy (e.g., femoral vein size, thrombus, or tortuosity).
    • Ability of the patient to tolerate general or local anesthesia.
    • Ability of the patient to undergo required imaging.
  • Ability to comply with the recommended post-WATCHMAN FLX Device implant pharmacologic regimen (see Post-Procedure Information section) especially for patients at high risk for bleeding.

ADVERSE EVENTS

Potential adverse events (in alphabetical order) which may be associated with the use of a left atrial appendage closure device or implantation procedure include but are not limited to:

  • Air embolism
  • Airway trauma
  • Allergic reaction to the contrast media, anesthetic, WATCHMAN Implant material, or medications
  • Altered mental status
  • Anemia requiring transfusion
  • Anesthesia risks
  • Angina
  • Anoxic encephalopathy
  • Arrhythmias
  • Atrial septal defect
  • Bruising, hematoma, or seroma near the catheter insertion site
  • Cardiac perforation
  • Chest pain/discomfort
  • Confusion post procedure
  • Congestive heart failure
  • Contrast related nephropathy
  • Cranial bleed
  • Death
  • Decreased hemoglobin
  • Deep vein thrombosis
  • Device embolism
  • Device fracture
  • Device thrombosis
  • Edema
  • Embolism
  • Excessive bleeding
  • Fever
  • Fistula
  • Groin pain
  • Groin puncture bleed
  • Hematuria
  • Hemoptysis
  • Hypotension
  • Hypoxia
  • Improper wound healing
  • Inability to reposition, recapture, or retrieve the device
  • Infection/pneumonia
  • Interatrial septum thrombus
  • Intratracheal bleeding
  • Major bleeding requiring transfusion
  • Misplacement of the device/improper seal of the appendage/movement of device from appendage wall
  • Myocardial erosion
  • Nausea
  • Oral bleeding
  • Pericardial effusion/tamponade
  • Pleural effusion
  • Prolonged bleeding from a laceration
  • Pseudoaneurysm
  • Pulmonary edema
  • Renal failure
  • Respiratory insufficiency/failure
  • Stroke - Hemorrhagic
  • Stroke - Ischemic
  • Surgical removal of the device
  • TEE complications (e.g., throat pain, bleeding, esophageal trauma)
  • Thrombocytopenia
  • Thrombosis
  • Transient ischemic attack (TIA)
  • Valvular or vascular damage
  • Vasovagal reactions

There may be other potential adverse events that are unforeseen at this time.

92574167 C.2